The demographical and clinical characteristics of subjects at baseline. by Soheila Qanbari (20455173)

Subjects:

Electrode montage and electric field distribution simulated with SimNIBS software. by Soheila Qanbari (20455173)

Subjects:

Join-point regression analysis of the statistically significant linear increase in use of antidepressants during the observed time period. by Jelena Filimonovic (22305307)

Significant changes in taxa at 30 days. by Arnon Gal (3150036)

Fitted estimates and significance levels of linear mixed models for seedling germination, survival and growth. by Laura García de Jalón (8939456)

Changes in the positive direction ratio as the time scale of the change direction increases. by Teruko Takada (13977607)

Comparison of with changed values of <i>λ</i> and M. by Siva Sankari (2827295)

Subjects:

Gut composition changes significantly during chemoradiotherapy, adapts after treatment, and remains altered at first follow-up. by Molly B. El Alam (10231830)

“…<p>The differential enrichments of bacterial phyla, classes, orders, families, and genera between baseline and week 5 were identified by linear discriminant analysis effect size. Significant differences are those with a logarithmic linear discriminant analysis score >4 and a factorial Kruskal-Wallis p-value <0.05. …”

Change in atmospheric CO₂ concentration, and thus surface warming, differs significantly across the different pathways for the same amount of emitted carbon. by Alexander J. Winkler (19287082)

Metabolites with significant changes between the groups. by José C. Páez-Franco (9722870)

Lipid droplets transiently increase in size during early stages of HSV-1 infection. by Kamal L. Nahas (13014698)

Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Subjects:

Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Subjects:

Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phas... by Naoya Itoh (6029276)

Subjects: